ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Sex-based molecular and prognostic disparities in pan-cancer: an analysis across the global cohorts.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBiological sex influences cancer risk, molecular profiles, and clinical outcomes, yet its role in non-reproductive cancers remains underexplored.
methodsThis study investigated sex-based differences in somatic mutations, copy number alterations (CNAs), and overall survival (OS) across 34,782 patients from three global pan-cancer cohorts (TCGA, MSK MetTropism, and China OrigiMed), excluding reproductive cancers to minimize confounders. Sex-specific genetic alterations were assessed using Fisher's exact test, while OS differences were evaluated with Kaplan-Meier and Cox proportional hazards models.
resultsIncidence patterns revealed a strong male predominance in esophageal, liver, bladder, and head and neck cancers, whereas thyroid and gallbladder cancers were more common in females. OS analysis showed a consistent female advantage in both primary and metastatic cohorts, with males experiencing poorer OS in lung adenocarcinoma, glioblastoma, and pancreatic adenocarcinoma, although colorectal cancer with hepatic metastases favored males. Mutational profiling revealed that the TP53, CDKN2A, and TTN mutations were more frequent in males, while EGFR, KRAS, BRAF, and PIK3CA mutations occurred more often in females. Notably, BRAF and EGFR mutations were associated with better survival in females. CNAs analysis demonstrated male-biased amplifications, including CCND1 and the FGF cluster in the China cohort, and MYC, CCND1, and ERBB2 in the TCGA and MSK cohorts. In contrast, MDM2 amplification was enriched in females in the China cohort.
conclusionThese findings highlight both shared and population-specific molecular differences and underscore the importance of integrating sex as a biological variable in cancer genomics, biomarker development, and clinical trial design.
Indexed as
Identifiers
41247419What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.